• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    NanoViricides, Inc. Common Stock (NY:NNVC)

    0.9650 -0.0350 (-3.50%)
    Official Closing Price Updated: 8:00 PM EST, Jan 30, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about NanoViricides, Inc. Common Stock

    < Previous 1 2 3 4 5 6 7 8 9 Next >
    News headline image
    RETRANSMISSION: NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025
    Via ACCESS Newswire
    InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) to Present at LSX World Congress 2025
    Via Investor Brand Network
    Topics Intellectual Property
    News headline image
    NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025
    Via ACCESS Newswire
    News headline image
    NanoViricides Reports NV-387’s Anti-Inflammatory Effects Could Combat Viral-Induced Cancer Resurgence
    Via AB Newswire
    News headline image
    A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials
    Via ACCESS Newswire
    BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Highlights NV-387 as Potential Treatment for Growing Measles Outbreaks
    Via Investor Brand Network
    Topics Intellectual Property
    News headline image
    Measles Cases Increasing Worldwide, Need the New NV-387 Broad-Spectrum Antiviral to Combat, Says NanoViricides
    Via ACCESS Newswire
    BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Highlights NV-387’s Broad Antiviral Potential and Strategic Value for Pandemic Preparedness
    Via Investor Brand Network
    Topics Intellectual Property
    News headline image
    NanoViricides Discusses the Multi-Billion-Dollar Potential of Its Broad-Spectrum Drug NV-387; Its Effectiveness Against Influenza, Coronaviruses, RSV, MPox and Now Measles Expected to Drive Value
    Via ACCESS Newswire
    News headline image
    12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
     
    Via Benzinga
    BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Reports Breakthrough Measles Drug Success in Humanized Animal Study
    Via Investor Brand Network
    Topics Intellectual Property
    News headline image
    Measles Now Has a Drug - NV-387 Broad-Spectrum Antiviral Successful in Animal Studies, says NanoViricides
    Via ACCESS Newswire
    BioMedNewsBreaks — NanoViricides, Inc. (NYSE American: NNVC) Highlights MPox Drug Progress as WHO Extends Global Health Emergency
    Via Investor Brand Network
    Topics Intellectual Property
    News headline image
    WHO Extended Global Emergency Status of MPox Epidemic - Development of Treatment for MPox with NV-387 is Timely, Says NanoViricides
    Via ACCESS Newswire
    InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Finalizes Adaptive Trial Design for MPox Drug NV-387
    Via Investor Brand Network
    Topics Intellectual Property
    News headline image
    Adaptive Clinical Protocol Design for Phase II MPox Clade I Treatment with a Novel Broad-Spectrum Drug NV-387 is Almost Complete, Reports NanoViricides
    Via ACCESS Newswire
    News headline image
    There is a Strong Business Case for Phase II Clinical Program for Treatment of MPox Infection Using NV-387, an Industry-Leading Broad-Spectrum Antiviral Drug Candidate
    Via ACCESS Newswire
    InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Highlights NV-387 as Broad-Spectrum Antiviral Candidate for COVID and Bird Flu Preparedness
    Via Investor Brand Network
    Topics Intellectual Property
    News headline image
    With Rising Variants of COVID and Bird Flu, the Single Broad-Spectrum Antiviral NV-387 Would be the Best Partner for Preparedness, Says NanoViricides' Dr. Diwan
    Via ACCESS Newswire
    BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Advances Measles Drug Program Amid Rising Global Outbreaks
    Via Investor Brand Network
    Topics Intellectual Property
    News headline image
    NanoViricides Measles Drug Development Animal Study is Imminent
    Via ACCESS Newswire
    News headline image
    NanoViricides (NNVC) to Unveil ‘Escape-Proof’ Antiviral Platform at Major Biotech Convention
    Via AB Newswire
    BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) to Present Breakthrough Antiviral Platform at BIO International Convention
    Via Investor Brand Network
    Topics Intellectual Property
    News headline image
    NanoViricides to Present at the BIO International Convention in Boston on Monday, June 16, 2025
    Via ACCESS Newswire
    InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Comments on FDA COVID Booster Policy, Highlights Antiviral Strategy
    Via Investor Brand Network
    Topics Intellectual Property
    News headline image
    The New Rational FDA COVID Vaccine Policy is Long Overdue, Says NanoViricides' Dr. Diwan
    Via ACCESS Newswire
    InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Advances NV-387 Antiviral Program, Prepares for Multiple Phase II Trials
    Via Investor Brand Network
    Topics Intellectual Property
    News headline image
    NanoViricides, Inc. Has Filed its Quarterly Report: Broad-Spectrum Antiviral NV-387 To Combat MPox Pandemic in Africa - Phase II Clinical Trial Update, Also Readying to Combat Measles Outbreaks, and to Tackle Bird Flu
    Via ACCESS Newswire
    BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Advances NV-387 Antiviral as Measles and MPox Resurge Globally
    Via Investor Brand Network
    Topics Intellectual Property
    News headline image
    Measles Cases Are Increasing Globally; MPox Continues to Be a Threat - Broad-Spectrum Antiviral Drug Could Be the Solution
    Via ACCESS Newswire
    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.